Cargando…
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Chronic myeloid leukemia (CML) has a markedly improved prognosis with the use of breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitors (BCR-ABL1 TKIs). However, approximately 40% of patients are resistant or intolerant to BCR-ABL1 TKIs. Hypoxia-inducible factor 1α (HIF-1α) is a h...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978365/ https://www.ncbi.nlm.nih.gov/pubmed/36195570 http://dx.doi.org/10.5483/BMBRep.2022-0095 |
_version_ | 1784899507316588544 |
---|---|
author | Tsubaki, Masanobu Takeda, Tomoya Matsuda, Takuya Kimura, Akihiro Tanaka, Remi Nagayoshi, Sakiko Hoshida, Tadafumi Tanabe, Kazufumi Nishida, Shozo |
author_facet | Tsubaki, Masanobu Takeda, Tomoya Matsuda, Takuya Kimura, Akihiro Tanaka, Remi Nagayoshi, Sakiko Hoshida, Tadafumi Tanabe, Kazufumi Nishida, Shozo |
author_sort | Tsubaki, Masanobu |
collection | PubMed |
description | Chronic myeloid leukemia (CML) has a markedly improved prognosis with the use of breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitors (BCR-ABL1 TKIs). However, approximately 40% of patients are resistant or intolerant to BCR-ABL1 TKIs. Hypoxia-inducible factor 1α (HIF-1α) is a hypoxia response factor that has been reported to be highly expressed in CML patients, making it a therapeutic target for BCR-ABL1 TKI-sensitive CML and BCR-ABL1 TKI-resistant CML. In this study, we examined whether HIF-1α inhibitors induce cell death in CML cells and BCR-ABL1 TKI-resistant CML cells. We found that echinomycin and PX-478 induced cell death in BCR-ABL1 TKIs sensitive and resistant CML cells at similar concentrations while the cell sensitivity was not affected with imatinib or dasatinib in BCR-ABL1 TKIs resistant CML cells. In addition, echinomycin and PX-478 inhibited the c-Jun N-terminal kinase (JNK), Akt, and extracellular-regulated protein kinase 1/2 (ERK1/2) activation via suppression of BCR-ABL1 and Met expression in BCR-ABL1 sensitive and resistant CML cells. Moreover, treatment with HIF-1α siRNA induced cell death by inhibiting BCR-ABL1 and Met expression and activation of JNK, Akt, and ERK1/2 in BCR-ABL1 TKIs sensitive and resistant CML cells. These results indicated that HIF-1α regulates BCR-ABL and Met expression and is involved in cell survival in CML cells, suggesting that HIF-1α inhibitors induce cell death in BCR-ABL1 TKIs sensitive and resistant CML cells and therefore HIF-1α inhibitors are potential candidates for CML treatment. |
format | Online Article Text |
id | pubmed-9978365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-99783652023-03-03 Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells Tsubaki, Masanobu Takeda, Tomoya Matsuda, Takuya Kimura, Akihiro Tanaka, Remi Nagayoshi, Sakiko Hoshida, Tadafumi Tanabe, Kazufumi Nishida, Shozo BMB Rep Article Chronic myeloid leukemia (CML) has a markedly improved prognosis with the use of breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitors (BCR-ABL1 TKIs). However, approximately 40% of patients are resistant or intolerant to BCR-ABL1 TKIs. Hypoxia-inducible factor 1α (HIF-1α) is a hypoxia response factor that has been reported to be highly expressed in CML patients, making it a therapeutic target for BCR-ABL1 TKI-sensitive CML and BCR-ABL1 TKI-resistant CML. In this study, we examined whether HIF-1α inhibitors induce cell death in CML cells and BCR-ABL1 TKI-resistant CML cells. We found that echinomycin and PX-478 induced cell death in BCR-ABL1 TKIs sensitive and resistant CML cells at similar concentrations while the cell sensitivity was not affected with imatinib or dasatinib in BCR-ABL1 TKIs resistant CML cells. In addition, echinomycin and PX-478 inhibited the c-Jun N-terminal kinase (JNK), Akt, and extracellular-regulated protein kinase 1/2 (ERK1/2) activation via suppression of BCR-ABL1 and Met expression in BCR-ABL1 sensitive and resistant CML cells. Moreover, treatment with HIF-1α siRNA induced cell death by inhibiting BCR-ABL1 and Met expression and activation of JNK, Akt, and ERK1/2 in BCR-ABL1 TKIs sensitive and resistant CML cells. These results indicated that HIF-1α regulates BCR-ABL and Met expression and is involved in cell survival in CML cells, suggesting that HIF-1α inhibitors induce cell death in BCR-ABL1 TKIs sensitive and resistant CML cells and therefore HIF-1α inhibitors are potential candidates for CML treatment. Korean Society for Biochemistry and Molecular Biology 2023-02-28 2023-01-31 /pmc/articles/PMC9978365/ /pubmed/36195570 http://dx.doi.org/10.5483/BMBRep.2022-0095 Text en Copyright © 2023 by the The Korean Society for Biochemistry and Molecular Biology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Tsubaki, Masanobu Takeda, Tomoya Matsuda, Takuya Kimura, Akihiro Tanaka, Remi Nagayoshi, Sakiko Hoshida, Tadafumi Tanabe, Kazufumi Nishida, Shozo Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title_full | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title_fullStr | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title_full_unstemmed | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title_short | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
title_sort | hypoxia-inducible factor 1α inhibitor induces cell death via suppression of bcr-abl1 and met expression in bcr-abl1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978365/ https://www.ncbi.nlm.nih.gov/pubmed/36195570 http://dx.doi.org/10.5483/BMBRep.2022-0095 |
work_keys_str_mv | AT tsubakimasanobu hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT takedatomoya hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT matsudatakuya hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT kimuraakihiro hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT tanakaremi hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT nagayoshisakiko hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT hoshidatadafumi hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT tanabekazufumi hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells AT nishidashozo hypoxiainduciblefactor1ainhibitorinducescelldeathviasuppressionofbcrabl1andmetexpressioninbcrabl1tyrosinekinaseinhibitorsensitiveandresistantchronicmyeloidleukemiacells |